EURO-SKI trial: cessation of TKI treatment in CML patients with deep molecular response

Press brief by François-Xavier Mahon, MD, PhD of University Hospital of Bordeaux, Bordeaux, France, on results of the EURO-SKI trial on cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia (CML) patients with deep molecular response held at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

Share this video  
3rd December 2016